Core Insights - Rui Jian Pharmaceutical has achieved significant milestones in the development of its Parkinson's disease cell therapy product NouvNeu001, becoming the first globally to receive Fast Track designation from the FDA and entering Phase II clinical trials in China [1][4] - Chengdu High-tech Zone is emerging as a key player in the biopharmaceutical industry, with a focus on innovative drug development and a robust ecosystem supporting various companies [3][12] Company Developments - Rui Jian Pharmaceutical's NouvNeu001 is the first iPSC-derived universal cell therapy for Parkinson's disease to gain Fast Track status from the FDA, while also progressing in clinical trials in China [1] - The company is also advancing other products, such as NouvNeu004 for multiple system atrophy, which has received approval for full-cycle clinical trials in China [4] - Recent funding of over 300 million yuan for Rui Jian Pharmaceutical will accelerate the development of its Parkinson's and ophthalmic treatment products [14] Industry Trends - Chengdu High-tech Zone has been recognized as a leading biopharmaceutical hub, ranking alongside other major innovation districts in China [3] - The region is witnessing a surge in innovative products, with multiple companies achieving significant breakthroughs in various therapeutic areas, including diabetes and cancer [7][5] - The biopharmaceutical industry in Chengdu is projected to exceed 128 billion yuan in scale by 2024, with over 3,000 companies contributing to this growth [7] Ecosystem and Collaboration - The development of Rui Jian Pharmaceutical is closely tied to the supportive ecosystem in Chengdu High-tech Zone, which includes a network of suppliers and clinical resources [8][10] - The establishment of the "Global New Drug Discovery Center" aims to integrate resources from over 3,000 biopharmaceutical companies in the region, enhancing collaboration and innovation [11] - The collaboration between enterprises and institutions, such as Sichuan University West China Hospital, is fostering a comprehensive innovation chain from research to commercialization [12][18] Policy and Financial Support - Chengdu High-tech Zone has implemented supportive policies and established a substantial investment fund to facilitate the growth of the biopharmaceutical sector [16][17] - The "Wutong Plan" provides a comprehensive service framework for biopharmaceutical companies, covering all stages from drug development to market entry [17] - The region's proactive approach in policy-making and capital investment is crucial in overcoming challenges in the biopharmaceutical innovation landscape [16][14]

36氪获悉，近期，睿健毅联医药科技（成都）有限公司（下称"睿健医药"）已完成一笔新的B+轮次融 资。本轮融资由北极光创投、创景资本、元希海河等机构共同投资，易凯资本任独家财务顾问。 本次募集资金将用于加速推进公司旗下帕金森病治疗产品NouvNeu001/NouvNeu003、眼科治疗产品 NouvSight001的临床研发，以及团队建设和产业化能力。 睿健医药成立于2017年，专注于小分子化学转录调控诱导多能干细胞（iPSC）产品开发。今年4月，睿 健医药就曾官宣一笔过亿元B+轮融资。公司的B轮次融资金额累计已超过3亿元。 睿健医药的核心产品NouvNeu001是一款化学诱导的功能型人源多巴胺能神经元前体细胞。此前完成 B+轮融资时，睿健医药创始人、CEO魏君曾对36氪介绍，该产品已启动多中心II期临床试验。此前的I 期临床中，NouvNeu001在移植15个月后的患者中"展现出了良好的安全性和耐受性"；同时，PET影像 分析也显示，随着移植时间增加，细胞在患者体内实现无免疫抑制剂状况下的长期存续。 创始人及投资人观点： 睿健医药创始人、CEO魏君表示，感谢新老投资人对睿健的信任和持续支持，也感谢易凯资本和睿 ...

Core Viewpoint - RuiJian Pharmaceutical has recently completed over 100 million yuan in Series B+ financing, led by Fengchuan Capital, to accelerate clinical trials and product development for its core pipeline targeting Parkinson's disease [4][5]. Financing and Growth - The company has raised over 200 million yuan in total from two rounds of Series B financing [5]. - RuiJian Pharmaceutical focuses on the development of small molecule chemical transcription regulation-induced pluripotent stem cell (iPSC) products since its establishment in 2017 [5]. Product Development and Clinical Trials - The core product NouvNeu001, aimed at treating Parkinson's disease, has recently entered Phase II clinical trials [5][6]. - Initial Phase I clinical results showed significant clinical improvement in motor functions and non-motor symptoms in patients after six months of cell transplantation [7]. - The product has demonstrated long-term efficacy, with some patients showing stable improvements in behavior and mobility beyond 60 weeks post-treatment [7]. Future Prospects and Regulatory Approvals - RuiJian Pharmaceutical is also developing NouvNeu003, targeting early-onset Parkinson's patients under 50, which has received approval for Phase I clinical trials [8]. - The company has made progress in overseas clinical research, with NouvNeu001's IND application approved in the U.S. and expected to start Phase I trials soon [8]. Market Position and Investor Insights - The founder and CEO, Dr. Wei Jun, emphasized the company's commitment to addressing clinical needs and providing innovative therapies that can potentially reverse disease progression [9]. - Investors express confidence in RuiJian Pharmaceutical's technology and its potential to become a leading player in the iPSC field, highlighting the significant social and commercial value of its products [10].